Agenus inc (AGEN)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Cash flows from operating activities:
Net income (loss)

-45,271

-30,851

-46,277

-51,867

17,435

-48,848

-33,730

-25,204

-54,262

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-17,103

-

-40,773

-28,319

-31,778

-15,607

-13,122

-40,410

-18,741

-25,978

-8,109

-8,041

-357

-5,777

-7,318

-11,141

-5,835

-5,440

-5,729

-6,922

6,767

-6,020

-5,534

-5,757

-5,963

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

1,700

1,661

1,678

1,683

1,640

1,543

1,636

1,551

1,558

1,444

1,504

1,529

1,527

1,289

1,138

1,275

1,244

554

517

440

445

564

429

322

266

138

136

164

147

135

394

543

549

556

562

566

567

Share-based compensation

2,397

3,048

3,084

1,917

1,843

1,930

1,905

1,585

2,205

5,345

1,954

2,751

2,377

4,487

2,383

1,555

4,762

2,219

773

2,952

1,492

971

1,278

1,468

953

835

766

1,816

709

723

812

1,860

907

999

443

562

642

Non-cash royalty revenue

13,156

351

12,204

9,264

8,605

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense

13,844

11,801

10,791

10,181

9,428

8,536

7,338

6,056

2,669

4,881

4,577

4,379

4,403

4,336

4,209

4,028

3,954

3,983

1,140

299

203

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

153

153

-

134

1,093

448

432

417

1,902

388

6,518

-362

-1,736

-252

Loss on disposal of assets

-

-

-

-

-

-27

-40

-3

-75

-43

29

20

-29

-

-

-

-

-

-

-

-

-3

0

0

-1

-41

0

-0

-17

-11

0

0

0

-

-

-

-6

Change in fair value of contingent obligations

-4,384

4,625

-1,781

213

2,748

121

-180

-6,292

5,016

-3,311

1,184

-865

-196

-9,401

10,975

721

-342

-623

-6,498

13,630

7,058

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on issuance of stock for settlement of milestone obligation

-

-

-

-

-

-

-

-

-

551

0

0

14

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of contingent obligations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,617

8,894

-

-512

0

0

-

-

-

-

-

-

-

-

Loss on modification of debt

-2,720

-

-

-

-

0

0

0

-10,767

-

-

-

-

-

-

-

-

0

0

0

-154

-

0

0

0

0

0

-3,322

0

-

-

-

-

-

-

-

-

Gain on sale of investment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

-13,649

13,965

123

1,409

-142

-5,130

-4,851

9,791

-6

-1,056

-1,752

-2,831

-4,577

1,068

915

-803

369

2,098

3,280

1,897

2,055

0

0

0

-1

0

-201

38

-388

921

-276

-33

-58

0

-0

0

-35

Inventories

-

-

-

-

-

0

0

-7

-17

-

-

-

-

-

-

-

-

0

0

0

-7

0

0

95

0

-3

-0

-11

0

-8

2

0

1

-

-

-

0

Prepaid expenses

-465

-3,012

-3,076

-4,563

-1,141

4,740

1,618

1,879

-27

274

1,847

2,302

4,028

-416

265

-9

811

9

301

-580

973

-171

337

-191

279

3

-83

-148

341

105

59

112

-268

-235

-59

-34

160

Accounts payable

1,190

-3,334

-2,543

6,503

-860

2,484

1,213

4,487

-2,818

639

2,232

-149

-1,076

1,692

-1,747

2,738

-2,263

1,401

468

-1,475

2,273

-81

597

-746

184

459

-27

-92

-149

158

-164

291

-467

320

143

-110

-248

Deferred revenue

-1,875

-8,651

9,748

-3,825

56,628

667

-262

-329

-473

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-652

-

-657

-1,092

-1,537

-2,507

-2,487

-2,682

23,635

-915

-1,466

-540

-688

-227

-377

-486

-381

1,368

-381

-388

2,109

-390

-371

-385

-385

Accrued liabilities and other current liabilities

-8,471

1,691

5,641

2,370

-2,605

3,081

1,095

2,651

-3,524

1,113

70

-2,084

-3,947

11,935

955

-190

5,575

1,175

4,878

2,786

724

705

-2,566

1,977

-1,433

-229

1,736

-617

1,026

-803

1,048

-876

1,174

-1,371

893

-571

779

Other operating assets and liabilities

-2,687

579

-1,125

-3,231

2,348

382

264

-2,047

1,514

505

-176

1,272

728

3,042

-875

21

-32

1,170

99

-662

10,930

344

-2,257

2,568

29

124

-76

-156

-74

-1,259

182

163

166

356

-44

109

170

Net cash (used in) provided by operating activities

-34,505

-31,780

-27,785

-35,704

76,587

-35,812

-24,502

-30,530

-40,251

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-9,495

-10,124

-

-4,430

-5,662

-3,895

-3,277

-3,635

-3,346

11,271

-4,180

-3,398

-4,025

-4,644

Cash flows from investing activities:
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-14,831

-

-23,819

-18,491

-21,532

-19,591

-18,010

-12,869

3,295

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from sale of plant and equipment

-

-

-

-

-

0

1

0

5

0

0

5

115

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

4

7

10

Cash acquired in acquisition

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

514

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of plant and equipment

644

1,056

839

1,261

1,501

601

820

681

1,495

753

960

988

417

4,328

5,027

1,627

1,536

772

1,294

1,199

323

1,714

334

598

172

66

155

214

377

204

-36

-65

0

0

4

6

43

Purchases of available-for-sale securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

4,998

Proceeds from sale of available-for-sale securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

14,534

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of held-to-maturity securities

-

-

-

-

-

-

-

-

-

-

0

4,975

9,960

-

4,988

14,971

34,923

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from securities held-to-maturity

-

-

-

-

-

-

-

-

-

-

10,000

0

5,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-5,262

-

24,984

18,400

-36,460

-27,941

-1,303

-16,197

14,210

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from sale of available-for-sale securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

450

0

0

-

-

-

-

-

-

-

-

Net cash used in investing activities

-644

-1,056

-839

-1,261

-1,501

-601

-819

-681

-1,490

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-15,141

341

-

294

-214

-377

-2

-36

-65

0

1

0

5,001

-5,032

Cash flows from financing activities:
Net proceeds from sale of equity

65,123

0

0

0

30,000

3,639

13,385

22,637

5,258

1,882

0

1,840

61,836

-

-

-

-

0

-13

74,683

35,000

0

0

125

56,667

3,331

20,856

2,274

0

0

3,239

4,466

2,758

-

-

-

-

Proceeds from employee stock purchases and option exercises

2,204

-

-

-

172

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net proceeds from issuance of common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

680

Payment of long-term debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from employee stock purchases and option exercises

-

-

-

-

-

-

-

0

1,061

-

491

38

304

90

621

34

437

11

281

573

1,108

101

65

0

84

0

53

15

35

1

46

17

12

0

39

0

42

Financing of plant and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

63

-14

-9

-

-13

-4

-17

-11

-15

-3

-7

-

-

-

-

Proceeds from issuance of long-term debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

100,000

0

9,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from sale of future royalties

-

-

-

-

-

0

15,000

0

189,878

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Transaction costs from sale of future royalties and milestones

-

-

-

-

-

0

0

0

494

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayments of debt

500

-

-

-

-

0

0

0

161,847

-

-

-

-

-

-

-

-

-0

0

277

833

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of contingent purchase price consideration

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-200

-5

206

8,180

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment under a purchase agreement for in-process research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

4,000

1,000

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of preferred stock dividends

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,185

-197

-197

-197

197

197

197

197

Payment of finance lease obligation

1,214

88

81

76

75

90

64

64

65

114

83

66

66

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of contingent royalty obligation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

400

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Payments of convertible notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

62,074

-

573

-4,656

-562

211

78,499

74,772

36,095

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from Issuance of Debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from (Repayments of) Debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-833

-833

-

-

-

-

-

-

-

-

-

-

-

-

Payment of contingent royalty obligation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

400

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

65,613

1,268

34

-76

30,097

43,428

28,494

22,573

33,791

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-722

55,908

-

20,896

2,107

18

-9

2,973

4,282

2,565

195

6,113

409

525

Effect of exchange rate changes on cash

12

102

147

452

69

-131

-166

-546

110

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

30,476

-31,466

-28,443

-36,589

105,252

6,884

3,007

-9,184

-7,840

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Effect of exchange rate changes on cash

-

-

-

-

-

-

-

-

-

-

-

-

435

-

303

-184

184

-115

289

-345

-12

272

174

139

13

-

0

0

0

-

-

-

-

-

-

-

-

Net (decrease) increase in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

42,415

-

2,040

-4,932

-58,372

-47,436

59,474

45,360

53,589

-12,671

-9,884

-25,220

46,139

-2,852

16,759

-3,769

-4,254

-3,289

-698

871

13,837

-3,983

2,715

1,385

-9,151

Supplemental cash flow information:
Cash paid for interest

204

299

305

308

312

333

283

279

276

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

276

-

282

279

276

282

283

285

201

143

164

173

193

212

214

149

3

-

-

-

-

-

-

-

-

Supplemental disclosures - non-cash activities:
Purchases of plant and equipment in accounts payable and accrued liabilities

246

-

-

-68

173

178

-682

521

283

745

-133

-107

463

-304

937

-270

333

-6

7

104

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Lease right-of-use assets obtained in exchange for new operating lease liabilities

7,467

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Lease right-of-use assets obtained in exchange for new finance lease liabilities

2,434

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of common stock, $0.01 par value, for acquisition of 4-Antibody AG

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

10,102

-

0

0

0

-

-

-

-

-

-

-

-

Contingent purchase price consideration

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-9,711,279

9,721,000

-

0

0

0

-

-

-

-

-

-

-

-

Deemed dividend on series A convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

2,906

0

0

0

0

-

-

-

-

Convertible note adjustment to equity for conversion option

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

5,580

Reclassification of derivative liability into equity

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

755

Issuance of common stock, $0.01 par value, as payment of long-term debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

953

0

-

-

-

-

-

-

-

-

-

-

-

-

Payment to Consultant [Member]
Issuance of common stock

12

25

18

0

38

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-